Value of F-18 FDG PET/CT for the Prediction of EGFR Mutation in Lung Cancer Patients

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06520189

Enrollment

Registered

2024-07-25

Start date

2024-10-01

Completion date

2028-10-01

Last updated

2024-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Brief summary

To detect value of F-18FDG PET/CT as a non-invasive method for the prediction of EGFR mutations in lung cancer patients.

Detailed description

* Globally, lung cancer cases and deaths are rising. In 2018, GLOBOCAN estimated 2.09 million new cases (11.6% of total cancer cases) and 1.76 million deaths (18.4% of total cancer deaths). It is the most frequent cancer and cause of cancer death in men. * Epidermal growth factor receptor (EGFR) mutations are the second most common oncogenic driver event in non-small cell lung cancer (NSCLC) and classical activating mutations are well defined as strong predictors for good clinical response to EGFR tyrosine kinase inhibitors (EGFRi). * Over the last decade, the introduction of tyrosine-kinase inhibitors (TKIs) has showed a remarkable paradigm shift in the treatment of non-small cell lung cancer (NSCLC). However, genetic testing is sometimes unavailable. * Data from previous studies that have investigated the value of F-18 FDG PET/CT for predicting EGFR status are conflicting.

Interventions

DEVICEF-18 FDGPET/CT

F-18 FDGPET/CT oncology protocol for lung cancer patients

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* NSCLC patients who underwent EGFR mutation testing. * All patients ≥ 18 years.

Exclusion criteria

* Time interval between EGFR sampling and PET/CT more than 1 month. * Patients had been treated before sampling for the gene alteration analysis * Patients with glucose level \< 200 mg/dl.

Design outcomes

Primary

Measure	Time frame	Description
• Assessment of semi-quantitative F-18 FDG PET/CT as a non-invasive method for prediction of EGFR mutations in lung cancer patients.	baseline	detection value of F-18 FDG PET/CT for the prediction of EGFR mutation in lung cancer patients.

Secondary

Measure	Time frame	Description
• Assessment of the relationship between degree of the tracer uptake and pathology of the lesion.	baseline	correlate between degree of the tracer uptake and pathology of the lesion

Contacts

Primary Contactwalaa Gamal Fathy, assistant lecturer

dr.walaa196@gmail.com01503995795

Backup ContactNahla Moustafa Mahmoud, Assistant professor

Nahla_bashank_2006@yahoo.com01009466255

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026